Clinical Trial Update: Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update showing initial dosing of BI 655130 in patients with palmoplantar pustulosis (a form of psoriasis); results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Palmoplantar Pustulosis
• Psoriasis

Drugs mentioned

• BI 655130

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2019-11-26